Biocryst Pharmaceuticals (BCRX) said Tuesday that a first-of-its-kind oral therapy for a rare, genetic disease called hereditary angioedema successfully reduced the rate of swelling “attacks” experienced by patients compared to placebo, achieving the main goal of a Phase 3 clinical trial.

But the magnitude of the benefit demonstrated by the Biocryst once-daily pill, called BCX7353, was relatively small, raising investor concerns that the new therapy, while convenient for patients, will find it difficult to compete against more effective injectable medicines already on the market.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy